Estée Lauder (ELC) has partnered with biotechnology company Serpin Pharma to explore anti-inflammatory research and develop new skincare ingredients.
The collaboration aims to enhance skincare longevity with new cosmetics.
This partnership promises global benefits for consumers seeking long-lasting skincare solutions.
The collaboration leverages Serpin Pharma’s expertise in anti-inflammatory research. It has led to the development of proprietary biotech technology that is effective in reducing inflammation and boosting cell resilience.
This technology targets serine protease inhibitors (SERPINs), a family of proteins that enhance the body’s natural ability to heal inflamed cells.
The two companies are exploring how this technology can address skin irritation, ageing, and sensitivity.
Ongoing scientific studies aim to demonstrate its potential in cosmetic formulations designed to visibly reduce skin ageing and irritation.
Estée Lauder global innovation and research and development executive vice president Carl Haney said: “This novel technology will advance our transformative innovation agenda by pushing the boundaries of breakthrough scientific discovery.
“In partnership with Serpin Pharma, we’re exploring powerful new biological pathways and cutting-edge biotech ingredients to rapidly mitigate visible skin irritation and sensitivity for our prestige beauty consumers worldwide.”
This collaboration builds on Estée Lauder’s experience in longevity science, biotechnology, and fermentation. The company is accelerating innovation by partnering with biotech firms to bring breakthrough technologies to market, creating advanced skincare solutions.
This initiative aligns with ELC’s “Beauty Reimagined” strategy, which focuses on fast-to-market, on-trend products in high-demand categories.
Estée Lauder is engaged in manufacturing, marketing, and selling skincare, makeup, fragrance, and hair care products. The firm also has global R&D and innovation centres.
Serpin Pharma executive chairperson, founder, and CEO Cohava Gelber said: “Serpin Pharma was founded on the principles of biomimicry and how nature solves for signs of trauma and injury.
“We’re taking a novel approach by tapping into the body’s innate mechanism for resolving inflammation.
“We are proud to partner with ELC to explore how our powerful biotechnology can be applied to cosmetics and skin care.”
